Company intelligence / Profile preview

Aditum Bio

Oakland, California, United Statesaditumbio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Aditum Bio operates a unique biotech venture capital and company formation model focused on rapidly translating scientific discoveries into innovative medicines. Founded by former Novartis leaders Joe Jimenez and Dr. Mark Fishman, it identifies promising drug candidates—often at the translational stage—and spins out dedicated companies to advance these assets through clinical proof-of-concept, typically up to or through Phase II trials. The firm has launched thirteen companies since its founding in 2019 and has achieved notable exits such as Versanis' $1.9 billion acquisition by Eli Lilly in August 2023.

Therapeutic areas: OtherPsychiatryImmunologyNeurology
Modalities: Monoclonal antibodySmall moleculeOther modalities possible depending on portfolio company assets
Industry: Investors

Drug pipeline

1 asset

LBL-051

Pre-clinical

Indications: Autoimmune disorders

Partnerships

Leads Biolabs (co-founder with newco "Oblenio Bio")various licensing partners per asset

Beyond the preview

Go deeper on Aditum Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aditum Bio.

Explore the full profile